Amgen terminated the partnership, not ADXS. Most likely because their cell-based therapy guy left the company.
Sure [noram], a big pharma would rather take a $65 million writeoff on a promising technology rather than spend $50,000 on a headhunter to hire a replacement worker. Sure.